<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385670</url>
  </required_header>
  <id_info>
    <org_study_id>InterSEPT</org_study_id>
    <nct_id>NCT01385670</nct_id>
  </id_info>
  <brief_title>InterSEPT: In‐Tunnel SeptRx European PFO Trial</brief_title>
  <acronym>InterSEPT</acronym>
  <official_title>InterSEPT: In‐Tunnel SeptRx European PFO Trial: A Prospective, Multi‐Center Study to Evaluate the Safety and Performance of the SeptRx IPO PFO Closure System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeptRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeptRx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety, performance, and effectiveness of the
      SeptRx IPO PFO Closure System in the treatment of Patent Foramen Ovale (PFO) in patients who
      are amenable to percutaneous closure of their PFO defects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Major Adverse Events defined as composite rate of all death, stroke, device embolization, tamponade, and device related re‐intervention or surgery</measure>
    <time_frame>One (1) month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Device success defined as PFO closure at 6 months post procedure by transesophageal echocardiography (TEE) with contrast valsalva bubble study.</measure>
    <time_frame>Six (6) months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Foramen Ovale, Patent</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Heart Septal Defects</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)</intervention_name>
    <description>Transcatheter PFO closure</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be ≥ 18 years of age and ≤ 70 years of age

          -  The patient is willing to comply with specified follow-up evaluations

          -  The patient or legally authorized representative has been informed of the nature of
             the study, agrees to its provisions and has been provided written Notice of Informed
             Consent, approved by the appropriate Ethics Committee (EC)

          -  PFO flat width of 4-14mm (approximate PFO balloon diameter of 2.5-9mm) and PFO length
             of 4-20mm

        Exclusion Criteria:

          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure

          -  Other medical illness (e.g., cancer, known malignancy, congestive heart failure, organ
             transplant recipient or candidate) or known history of substance abuse (alcohol,
             cocaine, heroin etc.)

          -  Known hypersensitivity or contraindication to aspirin, heparin,
             clopidogrel/ticlopidine, Nitinol, and/or contrast sensitivity that cannot be
             adequately pre‐medicated

          -  Currently participating in another investigational study, or participation in another
             clinical trial in the previous 3 months

          -  PFO flat width &lt;4mm or &gt;14mm to begin the trial. PFO flat width &lt;4mm or &gt;19mm when the
             second size device is ready

          -  PFO length &lt;4mm or &gt;20mm

          -  Active endocarditis, active bacterial infection, or other infection producing
             bacteremia or sepsis

          -  History of chronic or sustained arrhythmia

          -  Congenital or structural heart disease other than PFO

          -  Thrombus at the intended site of implant or documented venous thrombosis in venous
             access

          -  Severe pulmonary hypertension

          -  Vascular anatomy unable to accommodate the appropriate‐sized sheath for device
             introduction

          -  Acute appendicitis

          -  Confinement to bed (increased risk for clot formation)

          -  Prior cardiac surgery, including implantation of active cardiac devices
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beverly Tang, PhD</last_name>
    <phone>510-225-9170</phone>
    <phone_ext>102</phone_ext>
    <email>beverly.tang@septrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICPS: Institut Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-François Piéchaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Zimmermann WJ, Heinisch C, Majunke N, Staubach S, Russell S, Wunderlich N, Sievert H. Patent foramen ovale closure with the SeptRx device initial experience with the first &quot;In-Tunnel&quot; device. JACC Cardiovasc Interv. 2010 Sep;3(9):963-7. doi: 10.1016/j.jcin.2010.04.019.</citation>
    <PMID>20850097</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Beverly Tang</name_title>
    <organization>SeptRx, Inc.</organization>
  </responsible_party>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>PFO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

